Zoetis (ZTS) Long-Term Debt Repayments (2016 - 2023)

Zoetis (ZTS) reported Long-Term Debt Repayments of $1.4 billion for Q1 2023, up 170.0% quarter-over-quarter from $500.0 million in Q4 2020.

Zoetis (ZTS) Long-Term Debt Repayments (2016 - 2023) Analysis & Trends

Zoetis (ZTS) has 4 years of Long-Term Debt Repayments data on file, last reported at $1.4 billion in Q1 2023.

Long-Term Debt Repayments for Q1 2023 came in at $1.4 billion, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $1.4 billion (changed N/A YoY), and the FY2025 annual result was $1.4 billion, changed N/A from the prior year.
Long-Term Debt Repayments improved to $1.4 billion in Q1 2023 per ZTS's latest filing, from $500.0 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $1.4 billion in Q1 2023 and troughed at $500.0 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	23.00 Mn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	-
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	-
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	-
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	-
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	-
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	216,000.00
10	Liquidia	5.64 Bn	5.42 Bn	121.79 Mn	19.97 Mn

Download Data